About the Company
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis. It developed Skyrizi ($7.8 billion in 2023 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include Botox ($5.7 billion in 2023 revenues), Imbruvica to treat cancer ($3.6 billion in 2023 revenues), Rinvoq to treat arthritis ($4 billion in 2023 revenues), Venclexta to treat leukemia and lymphoma ($2.3 billion in 2023 revenues), Vraylar to treat schizophrenia and bipolar disorder ($2.7 billion in 2023 revenues), and Mavyret to treat Hepatitis C ($1.4 billion in 2023 revenues). The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.In 2023, Humira began facing competition from a biosimilar developed by Amgen. The company is also developing a drug for Parkinson's disease that could be a blockbuster drug in 2027 and is awaiting approval from the Food and Drug Administration for epcoritamab, a blood-cancer therapy under development in partnership with Genmab.The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ABBV News
Medincell, AbbVie link up in long-acting injectable development pact worth up to $1.9B
After proving the merits of its drug delivery platform last year with the approval of Teva’s long-acting schizophrenia drug ...
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
Medincell and AbbVie make injectable therapy development deal
Medincell has signed an agreement with AbbVie for the development of next-generation long-acting injectable therapies.
What's Going On AbbVie Stock On Friday?
AbbVie Inc (NYSE:ABBV) released an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the ...
Is AbbVie a Millionaire Maker?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) on behalf of investors concerning ...
AbbVie injectables deal with French biotech could be worth $1.9B
Medincell will receive $35 million upfront and be eligible for up to $1.9 billion in development and commercial milestone ...
May 31st Options Now Available For AbbVie (ABBV)
Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the May 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options ...
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Top Stock Reports for AbbVie, Salesforce & General Electric
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Salesforce, Inc. (CRM) ...
AbbVie Inc's Dividend Analysis
AbbVie Inc (NYSE:ABBV) recently announced a dividend of $1.55 per share, payable on 2024-05-15, with the ex-dividend date set ...
Loading the latest forecasts...